IP Library › Granted Patent US 7,378,239
Granted Patent B2
US 7,378,239 · App. 10/469,587 · Granted May 27, 2008

Method of differentiating between ulcerative colitis and Crohn's disease

Assignee: InDex Diagnostics AB
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,378,239
App. No.
10/469,587
Granted
May 27, 2008
Kind
B2
Abstract

The differentiation between ulcerative colitis and Crohn's disease is made possible by a multi-gene approach where gene expression profiles in biopsy samples obtained from inflamed, and optionally also non-inflamed, areas in the intestines of a patient are studied.

Claims (13)

1. A method for the differentiation between ulcerative colitis and Crohn's disease based on the analysis of gene expression level profiles in biopsy samples obtained from inflamed colon tissue of a human patient, comprising determining expression levels of at least two marker genes in a biopsy sample from inflamed colon tissue from the patient, wherein said at least two marker genes are SEQ ID NO: 1 and SEQ ID NO: 2, and wherein expression of SEQ ID NO: 1 in inflamed colon tissue and lack of expression of SEQ ID NO: 2 in inflamed colon tissue is indicative of ulcerative colitis.

2. The method according to claim 1 , further comprising determining the expression levels of SEQ ID NO: 1 and SEQ ID NO: 2 in a biopsy sample from non-inflamed colon tissue from the patient, wherein expression of SEQ ID NO: 1 in inflamed colon tissue and a lack of expression of SEQ ID NO: 1 in non-inflamed colon tissue, together with a lack of expression of SEQ ID NO: 2 in inflamed colon tissue and expression of SEQ ID NO: 2 in non-inflamed colon tissue, is indicative of ulcerative colitis.

3. The method according to claim 1 , wherein the expression of each marker gene is determined through nucleic acid amplification of said genes using gene specific primers, and determination of the amplification results.

4. The method according to claim 3 , wherein the nucleic acid amplification is performed using PCR and the gene specific primers are SEQ ID NOS: 13, 14, 15 and 16.

5. The method according to claim 3 , wherein the determination of the amplification results is performed using ethidium bromide staining and visualisation under UV light.

6. The method according to claim 2 , wherein the expression level of each marker gene is determined through nucleic acid amplification of said genes using gene specific primers and determination of the amplification results.

7. The method according to claim 1 , further comprising determining the expression level of SEQ ID NO: 3 in the inflamed colon tissue, wherein expression of SEQ ID NO: 3 in inflamed tissue is indicative of ulcerative colitis.

8. The method according to claim 7 , wherein the expression level of each marker gene is determined through nucleic acid amplification of said genes using gene specific primers, and determination of the amplification results.

9. The method according to claim 1 , further comprising determining the expression level of SEQ ID NO: 4 in the inflamed colon tissue, wherein expression of SEQ ID NO: 4 in inflamed tissue is indicative of ulcerative colitis.

10. The method according to claim 9 , wherein the expression level of each marker gene is determined through nucleic acid amplification of said genes using gene specific primers, and determination of the amplification results.

11. The method according to claim 1 , further comprising determining the expression level of SEQ ID NOS: 3, 4, 5, 6, and 7 in the inflamed colon tissue, wherein expression of SEQ ID NOS: 3, 4, 5, 6, and 7 in the inflamed tissue is indicative of ulcerative colitis.

12. The method according to claim 11 , wherein the expression level of each marker gene is determined through nucleic acid amplification of said genes using gene specific primers, and determination of the amplification results.

13. The method according to claim 12 , wherein the nucleic acid amplification is performed using PCR and the gene specific primers are SEQ ID NOS: 13-26.

Assignments (2)
CHANGE OF NAME AND ADDRESS Recorded May 2, 2007
From: INDEX PHARMACEUTICALS AB
To: INDEX DIAGNOSTICS AB
Reel/Frame 019241/0539 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 21, 2004
From: DIECKMANN, ANDREAS; LOFBERG, ROBERT; VON STEIN, OLIVER; VON STEIN, PETRA
To: INDEX PHARMACEUTICALS AB
Reel/Frame 014876/0700 →
Priority Claims (5)
SE 0201954-5 · Jun 25, 2002 · national
SE 0201956-0 · Jun 25, 2002 · national
SE 0202251-5 · Jul 18, 2002 · national
SE 0202252-3 · Jul 18, 2002 · national
SE 0202256-4 · Jul 18, 2002 · national
Continuity (6)
Provisional Application 6040921300 · Sep 10, 2002
Provisional Application 6040771300 · Sep 4, 2002
Provisional Application 6040768200 · Sep 4, 2002
Provisional Application 6039563100 · Jul 15, 2002
Provisional Application 6039562900 · Jul 15, 2002
Related Publication 20040241823A1 · Dec 2, 2004